Meeting of the Uniform Formulary Beneficiary Advisory Panel, 50088-50089 [2012-20413]

Download as PDF 50088 Federal Register / Vol. 77, No. 161 / Monday, August 20, 2012 / Notices Reserve Forces Policy Board until its next meeting. The Designated Federal Officer will review all timely submitted written statements and provide copies to all the committee members before the meeting that is the subject of this notice. Dated: August 15, 2012. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2012–20416 Filed 8–17–12; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Office of the Secretary Threat Reduction Advisory Committee; Notice of Federal Advisory Committee Meeting Department of Defense, Office of the Under Secretary of Defense (Acquisition, Technology and Logistics). ACTION: Federal advisory committee meeting notice. AGENCY: Under the provisions of the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense announces the following Federal advisory committee meeting of the Threat Reduction Advisory Committee (hereafter referred to as ‘‘the Committee’’). SUMMARY: Thursday, September 6, 2012, from 8:30 a.m. to 5 p.m. and Friday, September 7, 2012, from 8:30 a.m. to 3 p.m. ADDRESSES: Conference Room 3A912A, The Pentagon. FOR FURTHER INFORMATION CONTACT: Mr. William Hostyn, GS–15, DoD, Defense Threat Reduction Agency/J2/5/8R, 8725 John J. Kingman Road, MS 6201, Fort Belvoir, VA 22060–6201. Email: william.hostyn@dtra.mil. Phone: (703) 767–4453. Fax: (703) 767–4206. SUPPLEMENTARY INFORMATION: Purpose of Meeting: To obtain, review and evaluate classified information related to the Committee’s mission to advise on technology security, combating weapons of mass destruction (C–WMD), counter terrorism and counter proliferation. Agenda: Beginning at 8:30 a.m. on September 6, and through the end of the meeting on September 7, the committee will receive classified Combating Weapons of Mass Destruction (C–WMD) briefings from the Department of Defense and the Intelligence Community. The committee will also mstockstill on DSK4VPTVN1PROD with NOTICES DATES: VerDate Mar<15>2010 16:25 Aug 17, 2012 Jkt 226001 hold classified discussions on Middle East WMD concerns, the Cost Assessment and Program Evaluation Study, and Advance Smart Nuclear Awareness, Control and Accountability. Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.155, the Department of Defense has determined that the meeting shall be closed to the public. The Under Secretary of Defense for Acquisition, Technology and Logistics, in consultation with the DoD FACA Attorney, has determined in writing that the public interest requires all sessions of this meeting be closed to the public because the discussions will be concerned with classified information and matters covered by 5 U.S.C. 552b(c)(1) and are inextricably intertwined with the unclassified material which cannot reasonably be segregated into separate discussions without disclosing secret material. Committee’s Designated Federal Officer or Point of Contact: Mr. William Hostyn, GS–15, DoD, Defense Threat Reduction Agency/J/2/5/8R, 8725 John J. Kingman Road, MS 6201, Fort Belvoir, VA 22060–6201. Email: william.hostyn@dtra.mil. Phone: (703) 767–4453. Fax: (703) 767–4206. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140 and section 10(a)(3) of the Federal Advisory Committee Act of 1972, the public or interested organizations may submit written statements to the membership of the Committee at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Committee’s Designated Federal Officer. The Designated Federal Officer’s contact information is listed in FOR FURTHER INFORMATION CONTACT or it can be obtained from the GSA’s FACA Database—https://www.fido.gov/ facadatabase/public.asp. Written statements that do not pertain to a scheduled meeting of the Committee may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting then these statements must be submitted no later than five business days prior to the meeting in question. The Designated Federal Officer will review all submitted written statements and provide copies to all committee members. Dated: August 15, 2012. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2012–20415 Filed 8–17–12; 8:45 am] BILLING CODE 5001–06–P PO 00000 Frm 00011 Fmt 4703 Sfmt 4703 DEPARTMENT OF DEFENSE Office of the Secretary Meeting of the Uniform Formulary Beneficiary Advisory Panel Assistant Secretary of Defense (Health Affairs), DoD. ACTION: Notice of meeting. AGENCY: Under the provisions of the Federal Advisory Committee Act of 1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) the Department of Defense (DoD) announces the following Federal Advisory Committee Meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). DATES: September 27, 2012, from 9 a.m. to 1 p.m. ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, Building 1000 San Antonio, TX 78234–6012, Telephone: (210) 295–1271, Fax: (210) 295–2789, Email Address: Baprequests@tma.osd.mil. SUMMARY: SUPPLEMENTARY INFORMATION: Purpose of Meeting: The Panel will review and comment on recommendations made to the Director of TRICARE Management Activity, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. Meeting Agenda: 1. Sign-In. 2. Welcome and Opening Remarks. 3. Public Citizen Comments. 4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item). a. Androgens-Anabolic Steroids. b. Anticoagulants. c. Designated Newly Approved Drugs in Already-Reviewed Classes. d. Pertinent Utilization Management Issues. 5. Panel Discussions and Vote. Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. Administrative Work Meeting: Prior to the public meeting, the Panel will conduct an Administrative Work E:\FR\FM\20AUN1.SGM 20AUN1 mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 77, No. 161 / Monday, August 20, 2012 / Notices Meeting from 7:30 a.m. to 9 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue, NW., Washington, DC 20004. Pursuant to 41 CFR 102–3.160, the Administrative Work Meeting will be closed to the public. Written Statements: Pursuant to 41 CFR 102–3.105(j) and 102–3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained from the General Services Administration’s Federal Advisory Committee Act Database at https:// www.fido.gov/facadatabase/public.asp. Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel’s DFO will have a ‘‘Sign-Up Roster’’ available at the Panel meeting for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1 hour time period, no further public comments will be accepted. Anyone who signs-up to address the Panel, but is unable to do so due to the time limitation, may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel’s deliberation. To ensure timeliness of comments for the official record, the Panel encourages that individuals and interested groups consider submitting written statements instead of addressing the Panel. VerDate Mar<15>2010 16:25 Aug 17, 2012 Jkt 226001 Dated: August 15, 2012. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2012–20413 Filed 8–17–12; 8:45 am] BILLING CODE 5001–06–P 50089 microtubes and sensing fibers therein for evaluating and treating cell tissue. Brenda S. Bowen, Army Federal Register Liaison Officer. [FR Doc. 2012–20354 Filed 8–17–12; 8:45 am] BILLING CODE 3710–08–P DEPARTMENT OF DEFENSE DEPARTMENT OF DEFENSE Department of the Army Department of the Army Notice of Intent To Grant Exclusive License of the United States Patent No. 7,837,654 B2, Issued November 23, 2010 Entitled: Precision Sensing and Treatment Delivery Device for Promoting Healing in Living Tissue Department of the Army, DoD. ACTION: Notice of intent. AGENCY: In accordance with 37 CFR 404.7(a)(1)(i), announcement is made of a prospective exclusive license of the following U.S. Patent #7,837,654 B2, issued November 23, 2010, to OPTS, Inc., a Huntsville, Alabama company. DATES: Written objections must be filed not later than 15 days following publication of this announcement. ADDRESSES: United States Army Aviation & Missile Research Development & Engineering Center, Attn: RDMR–CST (Dr. J.R. Alexander), 5400 Fowler Road, Redstone Arsenal, Alabama 35898–5000. FOR FURTHER INFORMATION CONTACT: Dr. Russ Alexander, Chief, Office of Research and Technology Applications, (256) 876–8743, email: russ.alexander@us.army.mil SUMMARY: This patent abstract claims a microneedle insertable in a target cell tissue, including a manipulative end maintained exterior of cell tissue and an insertion end positionable in or adjacent of target cell tissue. A plurality of microtubes are bundled to pass through the needle body and extend to respective distal ends grouped proximally interior of the insertion end. A sensing fiber is extendable from means for sensing for passage through the needle body to a distal end capable of sensing cell tissue parameters. The insertion end and the bundled microtube and sensing fiber distal ends are positionable in or adjacent of cell tissue thereby providing rapid evaluation of cell parameters by optic fiber sensing, fiber sampling of cell parameters, and precise delivery of therapeutic fluids or additional treatment measures. A method is also disclosed of precisely positioning a microneedle having a plurality of SUPPLEMENTARY INFORMATION: PO 00000 Frm 00012 Fmt 4703 Sfmt 4703 Army Education Advisory Committee Meeting Department of the Army, DoD. Notice of open meeting. AGENCY: ACTION: Pursuant to the Federal Advisory Committee Act of 1972 (5 U.S.C., Appendix, as amended), the Sunshine in the Government Act of 1976 (U.S.C. 552b, as amended) and 41 Code of the Federal Regulations (CFR 102–3. 140 through 160, the Department of the Army announces the following committee meeting: Name of Committee: Army Education Advisory Committee (AEAC). Date of Meeting: September 4–5, 2012. Time of Meeting: 0800–1600. Place of Meeting: TRADOC HQ, 950 Jefferson Ave, Building 950, Conference Room 2047, 2rd Floor, Ft Eustis, VA. Proposed Agenda: Purpose of the meeting is to gather and review information, discuss, and deliberate issues related to shifting Army training from an instructor-centric to a learnercentric paradigm required by the Army 2020 learning environment. The agenda will include topics relating to Army Learning Model 2015 and support to essential proficiencies and professional development plan for facilitators. Additionally, recommendations submitted by subcommittees will be discussed and deliberated. FOR FURTHER INFORMATION CONTACT: For information please contact Mr. Wayne Joyner, Designated Federal Officer, at albert.w.joyner.civ@mail.mil, (757) 501– 5810, or to the following address: Army Education Advisory Committee, Designated Federal Officer, ATTN: ATTG–OPS–EO (Joyner), 950 Jefferson Ave, Building 950, Ft Eustis, Virginia 23604. SUMMARY: Meeting of the Advisory Committee is open to the public and any member of the public wishing to attend this meeting should contact the Designated Federal Officer previously listed at least ten calendar days prior to the meeting for information on base entry. Individuals without a DoD Government Common Access Card require an escort at the SUPPLEMENTARY INFORMATION: E:\FR\FM\20AUN1.SGM 20AUN1

Agencies

[Federal Register Volume 77, Number 161 (Monday, August 20, 2012)]
[Notices]
[Pages 50088-50089]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-20413]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and 
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended) 
the Department of Defense (DoD) announces the following Federal 
Advisory Committee Meeting of the Uniform Formulary Beneficiary 
Advisory Panel (hereafter referred to as the Panel).

DATES: September 27, 2012, from 9 a.m. to 1 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 4130 Stanley Road, Suite 208, 
Building 1000 San Antonio, TX 78234-6012, Telephone: (210) 295-1271, 
Fax: (210) 295-2789, Email Address: Baprequests@tma.osd.mil.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.
    Meeting Agenda:
    1. Sign-In.
    2. Welcome and Opening Remarks.
    3. Public Citizen Comments.
    4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item).
    a. Androgens-Anabolic Steroids.
    b. Anticoagulants.
    c. Designated Newly Approved Drugs in Already-Reviewed Classes.
    d. Pertinent Utilization Management Issues.
    5. Panel Discussions and Vote.
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space, this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing-in. All persons must sign-in 
legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work

[[Page 50089]]

Meeting from 7:30 a.m. to 9 a.m. to discuss administrative matters of 
the Panel. The Administrative Work Meeting will be held at the Naval 
Heritage Center, 701 Pennsylvania Avenue, NW., Washington, DC 20004. 
Pursuant to 41 CFR 102-3.160, the Administrative Work Meeting will be 
closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's Designated Federal Officer (DFO). The DFO's contact 
information can be obtained from the General Services Administration's 
Federal Advisory Committee Act Database at https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: August 15, 2012.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2012-20413 Filed 8-17-12; 8:45 am]
BILLING CODE 5001-06-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.